Milestone Launches Registry to Bolster Real-World Evidence for CARDAMYST

Event summary

  • Milestone Pharmaceuticals initiated the RESET-PSVT registry, a Phase 4, multicenter, prospective, observational study.
  • The registry aims to enroll approximately 450 adult patients across 20 sites, starting by the end of 2026.
  • RESET-PSVT will evaluate CARDAMYST (etripamil) usage patterns and patient-reported outcomes in PSVT management.
  • The study is being led by the Duke Clinical Research Institute (DCRI).

The big picture

The launch of RESET-PSVT underscores the growing emphasis on real-world evidence (RWE) in pharmaceutical marketing and post-approval studies. This registry represents a strategic effort by Milestone to expand CARDAMYST’s clinical utility beyond controlled trials and address the increasing demand for data demonstrating value in routine clinical practice. The reliance on the DCRI, a leading research institution, lends credibility to the findings and could influence physician prescribing behavior.

What we're watching

Enrollment Pace
The speed of patient enrollment will be a key indicator of the registry’s overall success and the willingness of clinicians to participate, potentially impacting the timeline for data generation.
Data Integrity
The reliability of patient-reported outcomes and survey data will be crucial for generating actionable insights and influencing treatment guidelines, requiring robust data validation processes.
Commercial Impact
The registry’s findings could significantly influence CARDAMYST’s market adoption and reimbursement landscape, particularly if they demonstrate improved patient quality of life or reduced healthcare utilization.

Related topics

Pharmaceuticals